Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
We haven't written up this one. CNBC World has the full story — the link below goes straight to it.